Roche to enter FGF21 space with $2.4B buyout of MASH biotech 89bionews2025-09-18T11:02:16+00:00September 18th, 2025|Endpoints News|
#EASD25: Lilly seeks Mounjaro approval for children with diabetes following Phase 3 hitnews2025-09-18T10:41:47+00:00September 18th, 2025|Endpoints News|
A new use for a very old drug: Aspirin cut risk of recurrence for some types of colorectal cancer in half news2025-09-18T08:55:09+00:00September 18th, 2025|Endpoints News|
Regeneron heads to FDA with treatment for very rare bone diseasenews2025-09-17T19:31:06+00:00September 17th, 2025|Endpoints News|
#EADV25: Next-gen psoriasis drugs seek to challenge existing treatment optionsnews2025-09-17T15:11:27+00:00September 17th, 2025|Endpoints News|
#EADV25: Leo Pharma details mid-stage win for IL-22 targeting antibody in atopic dermatitisnews2025-09-17T14:00:38+00:00September 17th, 2025|Endpoints News|
Lilly’s diabetes pill beats Novo’s Rybelsus in head-to-head trial, company mulls fast-track filingnews2025-09-17T13:00:43+00:00September 17th, 2025|Endpoints News|
Skyhawk reports positive first results in Huntington’s patients for oral drugnews2025-09-17T12:00:08+00:00September 17th, 2025|Endpoints News|
AstraZeneca’s Fasenra once again falls short in COPDnews2025-09-17T11:09:23+00:00September 17th, 2025|Endpoints News|
Roivant tees up dermatomyositis drug filing on heels of Phase 3 successnews2025-09-17T11:00:40+00:00September 17th, 2025|Endpoints News|
